Terms: = Ovarian cancer AND ETV6, TEL/ABL, 2120, ENSG00000139083, P41212, TEL
28 results:
1. Germline BRCA variants, lifestyle and ovarian cancer survival.
Gersekowski K; Delahunty R; Alsop K; Goode EL; Cunningham JM; Winham SJ; Pharoah P; Song H; Jordan S; Fereday S; DeFazio A; Friedlander M; Obermair A; ; ; Webb PM
Gynecol Oncol; 2022 Jun; 165(3):437-445. PubMed ID: 35400525
[TBL] [Abstract] [Full Text] [Related]
2. How challenging could be preoperative and intraoperative diagnosis of endometrial cancer?
Ferrero A; Attianese D; Villa M; Ravarino N; Menato G; Volpi E
Minerva Obstet Gynecol; 2023 Aug; 75(4):365-370. PubMed ID: 35191637
[TBL] [Abstract] [Full Text] [Related]
3. Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel: A Randomized Clinical Trial.
Landau C; Novak AM; Ganz AB; Rolnik B; Friedman E; Lev-Ari S
JAMA Netw Open; 2021 Dec; 4(12):e2139670. PubMed ID: 34962562
[TBL] [Abstract] [Full Text] [Related]
4. Survival and reproductive outcomes after fertility-sparing surgery performed for borderline epithelial ovarian tumor in Japanese adolescents and young adults: Results of a retrospective nationwide study.
Kuji S; Harada M; Yoshioka N; Kajiyama H; Satoh T; Mikami M; Shozu M; Enomoto T; Osuga Y; Suzuki N
J Obstet Gynaecol Res; 2022 Mar; 48(3):806-816. PubMed ID: 34951514
[TBL] [Abstract] [Full Text] [Related]
5. An SPRi Biosensor for Determination of the ovarian cancer Marker HE4 in Human Plasma.
Szymanska B; Lukaszewski Z; Zelazowska-Rutkowska B; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Sensors (Basel); 2021 May; 21(10):. PubMed ID: 34065481
[TBL] [Abstract] [Full Text] [Related]
6. Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy.
Zaborowski MP; Stefens-Stawna P; Osztynowicz K; Piorunek T; Batura-Gabryel H; Dyzmann-Sroka A; Kozubski W; Nowak-Markwitz E; Michalak S
Cancer Immunol Immunother; 2021 May; 70(5):1277-1289. PubMed ID: 33136178
[TBL] [Abstract] [Full Text] [Related]
7. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.
Osmanbeyoglu HU; Shimizu F; Rynne-Vidal A; Alonso-Curbelo D; Chen HA; Wen HY; Yeung TL; Jelinic P; Razavi P; Lowe SW; Mok SC; Chiosis G; Levine DA; Leslie CS
Nat Commun; 2019 Sep; 10(1):4369. PubMed ID: 31554806
[TBL] [Abstract] [Full Text] [Related]
8. Photodynamic therapy - hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity.
Plenagl N; Duse L; Seitz BS; Goergen N; Pinnapireddy SR; Jedelska J; Brüßler J; Bakowsky U
Drug Deliv; 2019 Dec; 26(1):23-33. PubMed ID: 30691327
[TBL] [Abstract] [Full Text] [Related]
9. Impact of right upper quadrant cytoreductive techniques with extensive liver mobilization on postoperative hepatic function and risk of liver failure in patients with advanced ovarian cancer.
Nasser S; Lathouras K; Nixon K; Campbell J; Stocks G; Jiao L; Fotopoulou C
Gynecol Oncol; 2018 Dec; 151(3):466-470. PubMed ID: 30278996
[TBL] [Abstract] [Full Text] [Related]
10. Prise en charge des fibromes utérins en présence d'une infertilité autrement inexpliquée.
Carranza-Mamane B; Havelock J; Hemmings R
J Obstet Gynaecol Can; 2016 Dec; 38(12S):S597-S608. PubMed ID: 28063569
[TBL] [Abstract] [Full Text] [Related]
11. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
Vasconcelos I; de Sousa Mendes M
Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
[TBL] [Abstract] [Full Text] [Related]
12. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract] [Full Text] [Related]
13. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathologic characteristics and prognostic factors of ovarian fibrosarcoma: the results of a multi-center retrospective study.
Huang L; Liao LM; Wang HY; Zheng M
BMC Cancer; 2010 Oct; 10():585. PubMed ID: 20979607
[TBL] [Abstract] [Full Text] [Related]
15. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.
Mine T; Matsueda S; Li Y; Tokumitsu H; Gao H; Danes C; Wong KK; Wang X; Ferrone S; Ioannides CG
Cancer Immunol Immunother; 2009 Aug; 58(8):1185-94. PubMed ID: 19048252
[TBL] [Abstract] [Full Text] [Related]
16. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract] [Full Text] [Related]
17. Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites.
Ishiyama S; Matsueda S; Jones LA; Efferson C; Celestino J; Schmandt R; Ioannides CG; Tsuda N; Chang DZ
Int J Oncol; 2007 Apr; 30(4):889-98. PubMed ID: 17332928
[TBL] [Abstract] [Full Text] [Related]
18. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
[TBL] [Abstract] [Full Text] [Related]
19. Late ovarian relapse of tel/AML1 positive ALL confirming that tel deletion is a secondary event in leukemogenesis.
Ly-Sunnaram B; Henry C; Gandemer V; Mee FL; Burtin F; Blayau M; Cayuela JM; Oster M; Clech P; Rambeau M; Marie C; Pampin C; Edan C; Gall EL; Goasguen JE
Leuk Res; 2005 Sep; 29(9):1089-94. PubMed ID: 16038737
[TBL] [Abstract] [Full Text] [Related]
20. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2.
Presneau N; Dewar K; Forgetta V; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2005 Jul; 43(3):141-54. PubMed ID: 15937959
[TBL] [Abstract] [Full Text] [Related]
[Next]
